Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin J Filshie, Olatoyosi Odenike, Anne-Marie Watson, Ravi Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Leah Hogdal, Ying Zhou, David Hoffman, Steve Kye, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 537.

https://doi.org/10.1182/blood-2021-145646

Published: 2021

Journal Articles

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Blood (2021) 138 (Supplement 1): 241.

https://doi.org/10.1182/blood-2021-145613

Published: 2021

Journal Articles

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Jacqueline S. Garcia, MD, Andrew H. Wei, Uma Borate, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Joseph G. Jurcic, MD, Meagan A. Jacoby, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Ilona Cunningham, MBBS, FRACP, FRCPA, Ying Zhou, PhD, Bo Tong, PhD, Leah Hogdal, PhD, Rajesh Kamalakar, MS, Jessica E. Hutti, PhD, Steve Kye, MD MPH, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 55–57.

https://doi.org/10.1182/blood-2020-139492

Published: 2020

Journal Articles

Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma

Melissa A. Fischer, PhD, Sharon Friedlander, PhD, Leah Hogdal, PhD, Pia Arrate, Hua Chang, PhD, Trinayan Kashyap, MS, Christian Argueta, PhD, Boris Klebanov, MA, MS, William Senapedis, PhD, Erkan Baloglu, PhD MBA, Margaret S. Lee, PhD, Sharon Shacham, PhD MBA, Michael R. Savona, MD

Blood (2016) 128 (22): 3949.

https://doi.org/10.1182/blood.V128.22.3949.3949

Published: 2016

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax

Joan Montero, PhD, Jason Stephansky, BS, Tianyu Cai, PhD, Gabriel K. Griffin, MD, Katsuhiro Togami, MD PhD, Lucia Cabal-Hierro, PhD, Nicole R. LeBoeuf, MD, Leah Hogdal, PhD, Ilene Galinsky, MSN, ANPc, Jon C. Aster, MD PhD, Matthew S. Davids, Naveen Pemmaraju, MD, Richard M. Stone, MD, Marina Konopleva, MD PhD, Anthony Letai, MD PhD, Andrew A. Lane, MD PhD

Blood (2016) 128 (22): 4045.

https://doi.org/10.1182/blood.V128.22.4045.4045

Published: 2016

Journal Articles

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Todd Rosenblat, MD, Mark L. Heaney, MD PhD, Joseph G Jurcic, MD, Azra Raza, MD, John G. Mears, MD, Ruth Santos, BS, Diana Carrillo, BS, David Shum, MS, Jacquelyn Gonzales, BSN, RN, Kevin Zikaras, BS, Martin Santos, BS, Rong Zhang, MS, Glorymar Ibanezs, MS, Leah Hogdal, BA, Jennifer Crombie, MD, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony G. Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2014) 124 (21): 974.

https://doi.org/10.1182/blood.V124.21.974.974

Published: 2014

Journal Articles

BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia

Leah Hogdal, Daniel J. DeAngelo, MD, Ph.D, Richard M. Stone, MD, Verena I. Gaidzik, MD, Donna Bucci, Konstanze Döhner, MD, Guido Marcucci, MD, Jeremy Ryan, SM, Anthony Letai, MD, PhD

Blood (2013) 122 (21): 238.

https://doi.org/10.1182/blood.V122.21.238.238

Published: 2013

NARROW

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only